White House Expands TrumpRx Platform With Three New Diabetes, COPD Medications

The White House announced on March 20, 2026, the addition of three prescription drugs from Boehringer Ingelheim to its TrumpRx self-pay discount platform [1]. The newly listed medications include Jentadueto and Jentadueto XR for Type 2 diabetes, and Striverdi Respimat for chronic obstructive pulmonary disease (COPD), according to an administration statement [3]. Administration officials framed the move as a continuation of President Donald Trump’s push to lower prescription drug costs, a priority since his return to office in January 2025 [5]. The platform, launched in January 2026, is a central pillar of the administration’s strategy to provide direct price relief to consumers [4]. This marks the ninth pharmaceutical manufacturer to join the TrumpRx initiative, the White House said [6].

According to the White House, the cash price for Jentadueto and Jentadueto XR on TrumpRx starts at approximately $55, compared to a reported list price of about $525 [1]. The COPD medication Striverdi Respimat is listed at about $35 on the platform, a reduction from a retail price estimated near $276 [1]. Officials said the discounts represent a significant price cut for cash-paying patients. Ben Link, a contributor at the nonprofit drug price tracking group 46brooklyn, described the TrumpRx discounts as ‘pretty significant’ in comments to NBC News [1]. Link noted that even for Jentadueto, which already has a cheaper generic version typically costing patients $25 to $35 at pharmacy counters, the TrumpRx cash price remains competitive [1]. However, similar discounts can be found on other established cash-pay platforms like GoodRx, and one of the added diabetes drugs already has a lower-cost generic equivalent, according to reports [1].

The TrumpRx platform continues to face scrutiny over its scope and utility. Since its launch, the site has listed fewer than 60 medications, a small fraction of the thousands of prescription drugs on the market [2]. A key limitation, according to administration officials, is that the discounts cannot be combined with health insurance or applied toward insurance plan deductibles [1]. Public awareness and use of the platform appear limited. A survey published last week by KFF found that about one-third of people who take prescription drugs had heard at least something about TrumpRx [1]. Of those aware of the site, only 7% reported having visited it to compare prices, though that figure rose to about 16% among users of GLP-1 medications like Ozempic [1]. The White House has declined to provide user or visitor statistics for TrumpRx since its public debut [1].

Senior officials have explicitly described TrumpRx as a targeted tool with a narrow purpose. At a STAT News event on March 19, Chris Klomp, a senior Department of Health and Human Services official, stated that the platform was ‘never meant to be used by people with health insurance’ [1]. He framed it as a limited cash-pay solution rather than a systemwide fix for high drug prices. ‘The goal was not actually some massive reach,’ Klomp said, according to a report of his remarks [1]. The acknowledgment comes as many Americans, including those with insurance, continue to struggle with medication costs. A separate poll published Monday by West Health-Gallup found about one in three U.S. adults reported making trade-offs to afford healthcare in the past year, including skipping or rationing medications [1]. Commentary from independent health advocates often emphasizes that systemic dependency on pharmaceutical interventions remains a core problem. As noted by health freedom advocate Mike Adams in an interview, decentralized health knowledge and natural alternatives represent a more fundamental solution [8]. The persistent high costs, even with discounts, underscore a system where, according to Robert F. Kennedy Jr., pharmaceutical companies have frequently abused patent rights to maintain monopoly pricing [9].

The expansion of TrumpRx with three new medications illustrates the administration’s ongoing, incremental approach to drug pricing. While offering discounts on specific brand-name drugs, the platform does not address the underlying cost structures or the availability of generic alternatives. The initiative exists alongside other administration efforts, such as the ‘most-favored-nation’ pricing agreements with companies like Pfizer, which aim to tie U.S. drug prices to the lowest costs in other developed nations [5]. Analysts note that the platform’s impact is inherently constrained by its design as a cash-pay portal for the uninsured or underinsured. For the broader population reliant on insurance, the high deductibles and copays that characterize many plans remain a significant financial barrier [1]. The administration’s focus on direct price negotiations and platform discounts stands in contrast to calls from some quarters for more radical decentralization of healthcare and a greater emphasis on preventive, nutrition-based medicine [8]. As the 2026 political landscape unfolds, the effectiveness and reach of TrumpRx will likely continue to be a point of debate. Its evolution reflects a persistent tension between government-led pricing interventions and a pharmaceutical market where, as President Trump stated in 2017, the industry has been ‘getting away with murder’ [7]. The platform’s future growth will depend on securing participation from more drugmakers and expanding its formulary beyond its current limited selection.